Houston rents actually rose in May. Sky Noir Photography by Bill Dickinson/Getty Images

The impact of COVID-19 has not been lost on the Houston housing market, with home sales dipping and rents rising. Here's a look at the current landscape.

Rising rents

In May, single-family home leases were up a solid 12 percent, notes the Houston Board of Realtors. This coincided with rising Houston rents.

According to Abodo's report, the median rent for a one-bedroom unit rose 0.51 percent month-over-month to $1,179, while two-bedroom rents gained 1.24 percent to a median $1,466. While one month's numbers don't necessarily mean a rental price spike, instead of Houston experiencing a COVID-19 price recession, we are currently seeing the opposite.

There are a number of reasons that trend could change, however. First, like potential homebuyers, would-be renters may want to stay safe and out of unfamiliar buildings. There is also anecdotal evidence that some apartment shoppers are worried about COVID-19 spreading in big complexes, and therefore the sprawling apartment complex market may be more negatively impacted than duplexes or other small housing uniques.

Dipping sales

"Houston home sales fell for a second straight month in May as the impact of COVID-19 and related stay-at-home orders continued to play out throughout the market," said the Houston Association of Realtors in its May report. "Homes in every pricing category suffered losses, with the steepest declines at the low and high ends of the market. Homes priced below $100,000 dropped more than 37 percent while those priced above $750,000 plunged more than 56 percent. Year-to-date sales are now running 4.3 percent behind 2019's record pace."

That's grim news, and even though mortgage rates are at record lows — good credit can get you a 15-year loan at 2.94 percent — many potential buyers are staying put. Conversely, some sellers are taking their homes off the market because of COVID-19 concerns.

Going virtual

While virtual tours and property management scheduling and showing tools are helping stay-at-home buyers make some purchasing decisions, very few will make a major home purchase without a careful in-person viewing. In addition, many sellers might struggle with the concept of selling their homes online.

However, renters are open to finding a new place virtually. Research from Abodo shows that "more than 60 percent of renters said that coronavirus has negatively impacted their apartment search. Additionally, 30 percent of renters surveyed stated they'd prefer photos and floorplans in a virtual manner, while pre-recorded videos of units (27 percent), and live personalized unit tours (21 percent) rounded out the pressing desires of renters."

Advances made now in virtual apartment shopping will have a market effect long past the current pandemic, and landlords would be well advised to adding virtual tour capabilities now.

Looking ahead

Some buyers and renters are staying on the sidelines waiting for a market crash, while others are gearing up for a steady recovery. As the pandemic continues, however, Abodo expects the Houston real estate and apartment rental economic activity to be stagnate at best.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”